ThermoGenesis Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:05 pm EST
Share
ThermoGenesis Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 2.19 million compared to USD 2.12 million a year ago. Net loss was USD 3.62 million compared to USD 3.24 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 4.66 a year ago.
For the nine months, sales was USD 7.04 million compared to USD 7.81 million a year ago. Net loss was USD 10.96 million compared to USD 7.84 million a year ago.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. It provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and the CAR-TXpress platform for large scale cell manufacturing services. Its products include Clinical Bio-Banking Applications, Point-of-Care Applications and Large-Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications include AXP Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large-Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory use and CAR-TXpress Platform for Clinical Manufacturing. AXP Automated Cell Separation System is an automated, fully closed cell separation system.